CJC-1295 no DAC (Mod GRF 1-29)

Modified fragment of GHRH (amino acids 1-29) with four amino acid substitutions for enzymatic stability. Stimulates pulsatile growth hormone release from the pituitary. Short half-life preserves natural GH secretion patterns. Synergistic when combined with GHRP or ghrelin mimetics.

Half-life

30 minutes

Bioavailability

Systemic via subcutaneous injection

Route

subcutaneous

Evidence tier

T2 — Single-RCT or mechanistic

Optimization pillars

anti-aging · recovery

References

1 peer-reviewed

Dose ranges

Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.

conservative

100 mcg 1-2x/day

Pulsatile GH support

moderate

100 mcg 2-3x/day

Enhanced GH pulsatility

aggressive

100–200 mcg 3x/day

Maximum pulsatile output

Monitoring

igf-1
fasting-glucose
fasting-insulin

Contraindications

active-cancer
pituitary-tumor

References

PMID:16352683Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 — J Clin Endocrinol Metab, 2006

Notes

Mod GRF 1-29 is the purist's GH peptide. Short half-life means it triggers a GH pulse and clears. Your pituitary responds, releases growth hormone in a physiological spike, then returns to baseline. This is how your body already works — you are amplifying the existing signal, not replacing it. Pair with ipamorelin for synergy. The GHRH + ghrelin mimetic combination produces GH output greater than either alone.

This is not medical advice

Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.

See CJC-1295 no DAC (Mod GRF 1-29) in a protocol matched to you